Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia
Response to proton pump inhibitors (PIP) was define as achieving less than 15 eosinophils/high-power field from baseline following at least a 8 weeks of PIP treatment (20-40mg twice a day of any of the available agents, prescribed at the discretion of the clinician). More studies are necessary to cl...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB145-AB145 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | AB145 |
|---|---|
| container_issue | 2 |
| container_start_page | AB145 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 141 |
| creator | Vera, Daiana Guillen De Las Cuevas, Natividad Barranco, Ruth Fernández-Crespo, Jesús Del Carmen Dieguez, Maria |
| description | Response to proton pump inhibitors (PIP) was define as achieving less than 15 eosinophils/high-power field from baseline following at least a 8 weeks of PIP treatment (20-40mg twice a day of any of the available agents, prescribed at the discretion of the clinician). More studies are necessary to clarify the differences in both entities and more experience are needed to determinate the role of periostin levels as biomarker for either diagnosis or monitoring of this entities. |
| doi_str_mv | 10.1016/j.jaci.2017.12.464 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2007522161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674917323643</els_id><sourcerecordid>2007522161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1241-249c571d1ca45c45eacd3bd3bb75282e5c341107d6afde0bb68699aa9cc4d7a13</originalsourceid><addsrcrecordid>eNp9kFtLAzEQhYMoWKt_wKcFn3fNZLOXgC9S6gUKLV6eQzY7tVnaZE22Bf-9WSrikzAwM3DOmeEj5BpoBhTK2y7rlDYZo1BlwDJe8hMyASqqtKxZcUomlApIy4qLc3IRQkfjntdiQrpX9PtdskJvXBiMTWLNXTDW9RuzNTpZYoij-jCDCYmybbLybnA2We13ffJsN6Yxg_PpC4be2WAO-OtAtf0bpS7J2VptA1799Cl5f5i_zZ7SxfLxeXa_SDUwDinjQhcVtKAVLzQvUOk2b2I1VcFqhoXOOQCt2lKtW6RNU9alEEoJrXlbKcin5OaY23v3uccwyM7tvY0nJaM0hjAoRxU7qrR3IXhcy96bnfJfEqgcmcpOjkzlyFQCk5FpNN0dTRj_Pxj0MmiDVmNrPOpBts78Z_8GkvyB4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007522161</pqid></control><display><type>article</type><title>Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Vera, Daiana Guillen ; De Las Cuevas, Natividad ; Barranco, Ruth ; Fernández-Crespo, Jesús ; Del Carmen Dieguez, Maria</creator><creatorcontrib>Vera, Daiana Guillen ; De Las Cuevas, Natividad ; Barranco, Ruth ; Fernández-Crespo, Jesús ; Del Carmen Dieguez, Maria</creatorcontrib><description>Response to proton pump inhibitors (PIP) was define as achieving less than 15 eosinophils/high-power field from baseline following at least a 8 weeks of PIP treatment (20-40mg twice a day of any of the available agents, prescribed at the discretion of the clinician). More studies are necessary to clarify the differences in both entities and more experience are needed to determinate the role of periostin levels as biomarker for either diagnosis or monitoring of this entities.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2017.12.464</identifier><language>eng</language><publisher>St. Louis: Elsevier Inc</publisher><subject>Blood diseases ; Eosinophilia ; Esophageal diseases ; Esophagitis ; Esophagus ; Leukocytes (eosinophilic) ; Proton pump inhibitors ; Protons</subject><ispartof>Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB145-AB145</ispartof><rights>2017</rights><rights>Copyright Elsevier Science Ltd. Feb 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2017.12.464$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Vera, Daiana Guillen</creatorcontrib><creatorcontrib>De Las Cuevas, Natividad</creatorcontrib><creatorcontrib>Barranco, Ruth</creatorcontrib><creatorcontrib>Fernández-Crespo, Jesús</creatorcontrib><creatorcontrib>Del Carmen Dieguez, Maria</creatorcontrib><title>Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia</title><title>Journal of allergy and clinical immunology</title><description>Response to proton pump inhibitors (PIP) was define as achieving less than 15 eosinophils/high-power field from baseline following at least a 8 weeks of PIP treatment (20-40mg twice a day of any of the available agents, prescribed at the discretion of the clinician). More studies are necessary to clarify the differences in both entities and more experience are needed to determinate the role of periostin levels as biomarker for either diagnosis or monitoring of this entities.</description><subject>Blood diseases</subject><subject>Eosinophilia</subject><subject>Esophageal diseases</subject><subject>Esophagitis</subject><subject>Esophagus</subject><subject>Leukocytes (eosinophilic)</subject><subject>Proton pump inhibitors</subject><subject>Protons</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kFtLAzEQhYMoWKt_wKcFn3fNZLOXgC9S6gUKLV6eQzY7tVnaZE22Bf-9WSrikzAwM3DOmeEj5BpoBhTK2y7rlDYZo1BlwDJe8hMyASqqtKxZcUomlApIy4qLc3IRQkfjntdiQrpX9PtdskJvXBiMTWLNXTDW9RuzNTpZYoij-jCDCYmybbLybnA2We13ffJsN6Yxg_PpC4be2WAO-OtAtf0bpS7J2VptA1799Cl5f5i_zZ7SxfLxeXa_SDUwDinjQhcVtKAVLzQvUOk2b2I1VcFqhoXOOQCt2lKtW6RNU9alEEoJrXlbKcin5OaY23v3uccwyM7tvY0nJaM0hjAoRxU7qrR3IXhcy96bnfJfEqgcmcpOjkzlyFQCk5FpNN0dTRj_Pxj0MmiDVmNrPOpBts78Z_8GkvyB4w</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Vera, Daiana Guillen</creator><creator>De Las Cuevas, Natividad</creator><creator>Barranco, Ruth</creator><creator>Fernández-Crespo, Jesús</creator><creator>Del Carmen Dieguez, Maria</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>201802</creationdate><title>Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia</title><author>Vera, Daiana Guillen ; De Las Cuevas, Natividad ; Barranco, Ruth ; Fernández-Crespo, Jesús ; Del Carmen Dieguez, Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1241-249c571d1ca45c45eacd3bd3bb75282e5c341107d6afde0bb68699aa9cc4d7a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood diseases</topic><topic>Eosinophilia</topic><topic>Esophageal diseases</topic><topic>Esophagitis</topic><topic>Esophagus</topic><topic>Leukocytes (eosinophilic)</topic><topic>Proton pump inhibitors</topic><topic>Protons</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vera, Daiana Guillen</creatorcontrib><creatorcontrib>De Las Cuevas, Natividad</creatorcontrib><creatorcontrib>Barranco, Ruth</creatorcontrib><creatorcontrib>Fernández-Crespo, Jesús</creatorcontrib><creatorcontrib>Del Carmen Dieguez, Maria</creatorcontrib><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vera, Daiana Guillen</au><au>De Las Cuevas, Natividad</au><au>Barranco, Ruth</au><au>Fernández-Crespo, Jesús</au><au>Del Carmen Dieguez, Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2018-02</date><risdate>2018</risdate><volume>141</volume><issue>2</issue><spage>AB145</spage><epage>AB145</epage><pages>AB145-AB145</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Response to proton pump inhibitors (PIP) was define as achieving less than 15 eosinophils/high-power field from baseline following at least a 8 weeks of PIP treatment (20-40mg twice a day of any of the available agents, prescribed at the discretion of the clinician). More studies are necessary to clarify the differences in both entities and more experience are needed to determinate the role of periostin levels as biomarker for either diagnosis or monitoring of this entities.</abstract><cop>St. Louis</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jaci.2017.12.464</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB145-AB145 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_journals_2007522161 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Blood diseases Eosinophilia Esophageal diseases Esophagitis Esophagus Leukocytes (eosinophilic) Proton pump inhibitors Protons |
| title | Serum Periostin in Eosinophilic Oesophagitis and Proton Pump Inhibitor-Responsive Oesophageal Eosinophilia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Periostin%20in%20Eosinophilic%20Oesophagitis%20and%20Proton%20Pump%20Inhibitor-Responsive%20Oesophageal%20Eosinophilia&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Vera,%20Daiana%20Guillen&rft.date=2018-02&rft.volume=141&rft.issue=2&rft.spage=AB145&rft.epage=AB145&rft.pages=AB145-AB145&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2017.12.464&rft_dat=%3Cproquest_cross%3E2007522161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007522161&rft_id=info:pmid/&rft_els_id=S0091674917323643&rfr_iscdi=true |